At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
GSK548470 300 mg tabletdrug
Likely dose
GSK548470 300 mg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open-label Study of GSK548470 (Tenofovir Disoproxil Fumarate) in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs
In Brief
A Phase 3 clinical trial evaluating GSK548470 300 mg tablet for Hepatitis B, Chronic. Completed, enrolled 34 participants across 11 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of once-daily treatment with GSK548470 300 mg in Japanese patients with compensated chronic hepatitis B with poor response to other drugs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionJun 2013
Study CompletionOct 2014
TodayJul 2026
First PostedNov 21, 2011
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2013
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.6 years ago
Interventions
GSK548470 300 mg tabletdrug
Blue tablets containing 300 mg of tenofovir disoproxil fumarate